What is Crysvita (burosumab) and what is it used for?
Crysvita is the brand name for burosumab, a monoclonal antibody that treats certain rare bone and mineral disorders caused by problems with phosphate regulation. It is used for:
- X-linked hypophosphatemia (XLH) in adults and children (including pediatric patients who are aged 1 year and older).
- Tumor-induced osteomalacia (TIO) in adults and children (including pediatric patients aged 2 years and older).
Crysvita works by blocking excess FGF23 activity, which helps the body retain and absorb phosphate and supports healthier bone mineralization [1].
How is Crysvita given, and what do dosing schedules look like?
Crysvita is given by injection under the skin (subcutaneous). The dosing is weight-based for pediatric patients and may differ by age group and indication.
Because the dosing schedule and adjustments can depend on the patient’s age, weight, and lab results (especially blood phosphate), clinicians typically tailor the plan to the individual [1].
What side effects are associated with Crysvita?
Commonly reported side effects can include:
- Injection-site reactions
- Headache
- Tooth-related problems (reported more often in some XLH monitoring contexts)
- Changes in blood chemistry such as low phosphate is less typical if treated appropriately, but electrolyte and mineral levels are monitored during therapy [1]
Patients are usually advised to report symptoms that could suggest hypersensitivity (for example, rash or breathing difficulty) because monoclonal antibodies can trigger immune reactions.
How is treatment monitored (phosphate levels and bone outcomes)?
Clinicians monitor blood phosphate levels to guide dosing and ensure the drug is improving phosphate handling. They also track clinical signs related to bone health and growth (in children) and may monitor imaging or dental status depending on the condition and treatment goals [1].
What should patients ask about before starting Crysvita?
Patients often want clarity on:
- Eligibility for XLH vs TIO based on age and diagnosis
- How often injections are scheduled and how dose changes are handled
- Expected time frame for phosphate changes and symptom improvement
- Dental monitoring needs and oral health planning
- Insurance coverage and authorization requirements, since biologics can be costly
Are there alternatives to Crysvita?
For XLH and TIO, other approaches may include conventional phosphate supplements plus active vitamin D analogs or other supportive management strategies. However, whether an alternative is appropriate depends on the specific diagnosis, severity, age, and prior treatment history. Clinicians choose between options based on how the condition is driven and on monitoring needs [1].
Sources
[1] https://www.crysvita.com/why-crysvinta.html